A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 28 Jun 2016 Results of cohort of a patients with HCV genotype 4 subtypes (n=44) published in the Hepatology
    • 17 Apr 2016 Results of an integrated analysis from five trials (n=236) presented at The International Liver Congress™ 2016
    • 13 Jan 2016 According to ClinicalTrials.gov record,Number of treatment arms changed from 4 to 2.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top